Skip to main content

Mindray Medical International



) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.4%. By the end of trading, Mindray Medical International fell $1.41 (-4.4%) to $30.48 on heavy volume. Throughout the day, 1.5 million shares of Mindray Medical International exchanged hands as compared to its average daily volume of 439,100 shares. The stock ranged in price between $29.86-$31.62 after having opened the day at $31.31 as compared to the previous trading day's close of $31.89. Other company's within the Health Care sector that declined today were:




), down 59.7%,

Rexahn Pharmaceuticals



), down 18.4%,

Idera Pharmaceuticals



), down 16.7%, and

TheStreet Recommends

K-V Pharmaceutical Company



), down 15.5%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $3.73 billion and is part of the

health services

industry. The company has a P/E ratio of 22.1, below the average health services industry P/E ratio of 23.2 and above the S&P 500 P/E ratio of 17.7. Shares are up 24.4% year to date as of the close of trading on Thursday. Currently there are six analysts that rate Mindray Medical International a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Mindray Medical International as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front,

Alexza Pharmaceuticals



), up 44.9%,

Response Genetics



), up 29.1%,




), up 20.6%, and

Geron Corporation



), up 15.4%, were all gainers within the health care sector with

Eli Lilly and Company



) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care